Scholarlink

<p>The role of the androgen receptor (AR) in breast cancer (BC) remains incompletely understood. Here, we conducted a meta-analysis of large-scale microarray transcriptomic datasets to evaluate whether the mRNA expression levels of the androgen receptor gene, relative to those of the estrogen receptor gene (<i>AR/ESR1</i> ratio) and the progesterone receptor gene (<i>AR/PGR</i> ratio), can help differentiate BC tumor subtypes. Additionally, we used qRT-PCR assays to assess the mRNA levels of the <i>AR/ESR1</i> and <i>AR/PGR</i> ratios in four cell lines representative of different BC subtypes (MCF7, BT474, MDA-MB453, and MDA-MB231), as well as in breast tissue from a small group of patients (11 cases) stratified by estrogen receptor (ER) status. Our results showed that higher <i>AR</i> gene expression relative to <i>ESR1</i> and <i>PGR</i> (≥ 2.0 and ≥ 1.54, respectively) were associated with BC patients classified under the Luminal B and HER2-enriched subtypes. Positive values of <i>AR/ESR1</i> and <i>AR/PGR</i> ratios were also observed in the ER-negative (ER-) cell line MDA-MB453, as well as in tumor tissue from ER- BC patients. Our findings confirm that higher or even positive <i>AR/ESR1</i> and <i>AR/PGR</i> ratios may be associated with BC cases exhibiting more aggressive clinical and biological features, leading to a worse prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

mRNA ratios of AR to ESR1 and PGR distinguish breast cancer subtypes based on public datasets and experimental models

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Diego Prieto,
  • Milena Rondón-Lagos,
  • Paola Cruz-Tapias,
  • Andrés Rincón-Riveros,
  • Wilson Rubiano,
  • Jairo De la Peña,
  • Elizabeth Vargas,
  • Victoria E. Villegas,
  • Nelson Rangel

摘要

The role of the androgen receptor (AR) in breast cancer (BC) remains incompletely understood. Here, we conducted a meta-analysis of large-scale microarray transcriptomic datasets to evaluate whether the mRNA expression levels of the androgen receptor gene, relative to those of the estrogen receptor gene (AR/ESR1 ratio) and the progesterone receptor gene (AR/PGR ratio), can help differentiate BC tumor subtypes. Additionally, we used qRT-PCR assays to assess the mRNA levels of the AR/ESR1 and AR/PGR ratios in four cell lines representative of different BC subtypes (MCF7, BT474, MDA-MB453, and MDA-MB231), as well as in breast tissue from a small group of patients (11 cases) stratified by estrogen receptor (ER) status. Our results showed that higher AR gene expression relative to ESR1 and PGR (≥ 2.0 and ≥ 1.54, respectively) were associated with BC patients classified under the Luminal B and HER2-enriched subtypes. Positive values of AR/ESR1 and AR/PGR ratios were also observed in the ER-negative (ER-) cell line MDA-MB453, as well as in tumor tissue from ER- BC patients. Our findings confirm that higher or even positive AR/ESR1 and AR/PGR ratios may be associated with BC cases exhibiting more aggressive clinical and biological features, leading to a worse prognosis.